Sign In
Buy ABMD
$381.02
+0 (+0%)
At Close: Mar 20, 2023
Abiomed (ABMD) Beats Q2 Earnings Estimates
09:47am, Tuesday, 01'st Nov 2022
Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
J&J to buy Abiomed in $16.6B deal to boost cardiovascular business
07:40am, Tuesday, 01'st Nov 2022
J&J's cardiovascular devices business will benefit from the $16.6 billion deal to acquire Abiomed. The deal comes at a time when J&J is spinning off its consumer health business.
Johnson & Johnson to buy medtech company Abiomed for $380 per share in cash
07:12am, Tuesday, 01'st Nov 2022
Johnson & Johnson is set to buy medical device company Abiomed in cash for $380 per share. CNBC's 'Squawk Box' team breaks down the deal.
Abiomed Stock Surges on Johnson & Johnson Takeover
07:07am, Tuesday, 01'st Nov 2022
The pharmaceutical giant will buy the heart-pump maker for $380 a share.
Abiomed stock rockets after J&J buyout deal valued at $16.6 billion
06:43am, Tuesday, 01'st Nov 2022
Shares of Abiomed Inc. ABMD, -2.32% rocketed 48.8% toward a 14-month high in premarket trading Tuesday, after the provider of medical technology that supports circulation and oxygenation agreed to acq
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
03:35pm, Monday, 31'st Oct 2022 Zacks Investment Research
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
04:45pm, Friday, 28'th Oct 2022 Zacks Investment Research
Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
Is Abiomed (ABMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
02:18pm, Friday, 28'th Oct 2022
Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.
The Zacks Analyst Blog Highlights Nevro, Masimo, Abiomed and Glaukos
11:36am, Friday, 28'th Oct 2022 Zacks Investment Research
Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
12:51pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
10:33am, Thursday, 27'th Oct 2022
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.
Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline
02:01pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Abiomed (ABMD) Stock Options
05:50pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Investors need to pay close attention to Abiomed (ABMD) stock based on the movements in the options market lately.
McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?
03:31pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
02:09pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.
